Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time, and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space. While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes, vast areas of the tropics remain understudied. In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity, but it remains among the least known forests in America and is often underrepresented in biodiversity databases. To worsen this situation, human-induced modifications may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge, it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost

Consensus Of Systemic Lupus Erythematosus [consenso De Lúpus Eritematoso Sistêmico]

[No abstract available]484196207Bus, V., Maury, E.E., Hochberg, M.C., The epidemiology of systemic lupus crythematosus (2007) Dubois lupus crythematosus, pp. 34-44. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins;Tan, E.M., Cohen, A.S., Fries, J.F., The 1982 revised criteria for the classification of systemic lupus erythematosus (1982) Arthritis Rheum, 25, pp. 1271-1277Hochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (1997) Arthritis Rheum, 40, p. 1725Dellavance, A., Gabriel, A., Cintra, A.F.U., II Consenso Brasileiro de Fator Antinuclear em Células HEP-2. Dcfinições para padronização da pesquisa contra constituintes do núcleo, nucléolo, citoplasma e aparelho mitótico e suas associações clínicas. (2003) Rev Bras Reumatol, 43, pp. 129-140Wallace, D.J., Principles of therapy and local measures (2007) Dubois lupus erythematosus, pp. 1132-1144. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins;Tench, C.M., McCarthy, J., McCurdie, I., Fatigue in systemic lupus erythematosus: A randomized controlled trial of exercise (2003) Rheumatology (Oxford), 42 (9), pp. 1050-1054Keyser, R.E., Rus, V., Cade, W.T., Kalappa, N., Flores, R.H., Handwerger, B.S., Evidence for aerobic insufficiency in women with systemic Lupus erythematosus (2003) Arthritis Rheum, 49 (1), pp. 16-22Carvalho, M.R., Sato, E.I., Tebexreni, A.S., Effects of supervised cardiovascular training program on exercise tolerance, aerobic capacity, and quality of life in patients with systemic lupus erythematosus (2005) Arthritis Rheum, 53 (6), pp. 838-844Ayán, C., Martín, V., Systemic Jupus erythematosus and exercise (2007) Lupus, 16 (1), pp. 5-9Measurement of fatigue in systemic lupus erythematosus: A systematic review (2007) Arthritis Rheum, 57 (8), pp. 1348-1357. , Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria for FatigueCarvalho, J.F., Blank, M., Kiss, E., Anti-vitamin D, vitamin D in SLE: Preliminary results (2007) Ann N Y Acad Sci, 1109, pp. 550-557Kamen, D.L., Cooper, G.S., Bouali, H., Vitamin D deficiency in systemic lupus erythematosus (2006) Autoimmun Rev, 5 (2), pp. 114-117Rahman, P., Gladman, D.D., Urowitz, M.B., Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus (1998) J Rheumatol, 25 (9), pp. 1716-1719Jewell, M.L., McCauliffe, D.P., Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment (2000) J Am Acad Dermatol, 42 (6), pp. 983-987Ghaussy, N.O., Sibbitt Jr, W., Bankhurst, A.D., Qualls, C.R., Cigarette smoking and disease activity in systemic lupus erythematosus (2003) J Rheumatol, 30 (6), pp. 1215-1221Westerweel, P.E., Luyten, R.K., Koomans, H.A., Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus Arthritis Rheum 20071, 56 (5), pp. 1384-1396Meinao, I.M., Sato, E.I., Andrade, L.E., Controlled trial with chloroquine diphosphate in systemic lupus erythematosus (1996) Lupus, 5, pp. 237-241A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus (1991) N Engl J Med, 324, pp. 150-154. , The Canadian Hydroxychloroquine Study GroupSachet, J.C., Borba, E.F., Bonfá, E., Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients (2007) Lupus, 16 (4), pp. 273-278Borba, E.F., Bonfa, E., Long term beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy (2001) J Rheumatol, 28, pp. 780-785Wallace, D.J., Linker-Israeli, M., Metzger, A.L., Stecher, V.J., The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE (1993) Lupus, 2 (SUPPL. 1), pp. S13-S15Kirou, K.A., Boumpas, D.T., Systemic glucocorticoid therapy in systemic lupus erythematosus (2007) Dubois lupus erythematosus, pp. 1175-1197. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins;Boumpas, D.T., Chrousos, G.P., Wilder, R.L., Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates (1993) Ann Intern Med, 119, pp. 1198-1208Maccune, W.J., Marder, W.E., Riskalla, M., Immunossuppressive drug therapy (2007) Dubois lupus erythematosus, pp. 1198-1224. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins;Carneiro, J.R., Sato, E.I., Double blind, randomized, placebo controlled clinical trial of methotrexatc in systemic lupus erythematosus (1999) J Rheumatol, 26, pp. 1275-1279Walchner, M., Messer, G., Kind, P., Phototesting and photoprotection in LE (1997) Lupus, 6, pp. 167-174Vila, L.M., Mayor, A.M., Valentin, A.H., Association of sunlight exposure and photoprotection measures with clinical outcome. in systemic lupus erythematosus (1999) P R. Health Sci J, 18, pp. 89-94Maggio, K.L., Singer, M.T., James, W.D., Clinical pearl: Discoid lupus erythematosus - treatment with occlusive compression (1996) J Am Acad Dermatol, 35, pp. 627-628Rangel, L.V., Santiago, J.M., Souza, J.C.C., Terapia tópica com pimecrolimus ern lesão cutânea refratária de lupus eritematoso sistêmica. (2006) Rev Bras Reumatol, 46, pp. 230-233Luger, T., Paul, C., Potential new indications of topical calcineurin inhibitors (2007) Dermatology, 215 (SUPPL. 1), p. 45Costner, M.I., Sontheimer, R.D., Provost, T.T., Lupus erythematosus (2003) Cutaneous manifestations of rheumatic diseases, pp. 15-64. , Sontheimer RD, Provost TT, editors, Philadelphia: Lippincott Williams & Wilkins;Wenzel, J., Brähler, S., Bauer, R., Tüting, T., Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: Results of a retrospective study in 43 patients (2005) Br J Dermatol, 153, pp. 157-162Callen, J.P., Spencer, L.V., Burruss, J.B., Holtman, J., Azathioprine: An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitis (1991) Arch Dermatol, 127, pp. 515-522Davis, J.C., Klippel, J.H., (2004) Antimalarials and immunossupressive therapies, pp. 1279-1281. , Systemic Lupus Erythematosus. 4th edBezerra, E.L.M., Vilar, M.J.P., Trindade Neto, P.B., Sato, E.I., Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus (2005) Arthritis Rheum, 52, pp. 3073-3078Hall, R.P., Lawley, T.J., Smith, H.R., Katz, S.I., Bullous eruption of systemic lupus erythematosus: Dramatic response to dapsone therapy (1982) Ann Intern Med, 97, pp. 165-170Cotell, S., Robinson, N.D., Chan, L.S., Autoimmune blistering skin diseases (2000) Am J Emerg Med, 18, pp. 288-299Atra, E., Sato, E.I., Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide (1993) Clin Exp Rheumatol, 11, pp. 487-493Coelho, A., Souto, M.I., Cardoso, C.R., Long-term thalidomide use in refractory cutaneous lesions in systemic lupus erythematosus: A 65 series of Brazilian patients (2005) Lupus, 14, pp. 434-439Pisoni, C.N., Obermoser, G., Cuadrado, M.J., Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: Poor results with mycophenolate mofetil (2005) Clin Exp Rheumatol, 23, pp. 393-396Schanz, S., Ulmer, A., Rassner, G., Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil (2002) Br J Dermatol, 147, pp. 174-178Horizon, A.A., Weisman, M.H., Nonsteroidals and salicylates for systemic lupus erythematosus (2007) Dubois lupus erythematosus, pp. 1145-1151. , Wallace DJ, Hahn BH, editors, 7th ed. Philadelphia: Lippincott Williams & Wilkins;Williams, H.J., Egger, M.J., Singer, J.Z., Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus (1994) J Rheumatol, 21, pp. 1457-1462Rahman, P., Humphrey-Murto, S., Gladman, D.D., Urowitz, M.B., Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis (1998) J Rheumatol, 25, pp. 243-246Quismorici Jr, F.P., Hematologic and lymphoid abnormalities in systemic lupus erythematosus (2007) Dubois lupus erythematosus, pp. 801-828. , Wallace DJ, Hahn BH, editors, Philadelphia: Lippincott Williams & Wilkins;Gomard-Menesson, E., Ruivard, M., Koenig, M., Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases (2006) Lupus, 15, pp. 223-231Jacob, H.S., Pulse steroids in hematologic diseases (1985) Hosp Pract (Off Ed), 20, pp. 87-94Pirofsky, B., Immune haemolytic disease: The autoimmune haemolytic anaemias (1975) Clin Haematol, 4, pp. 167-180Aviña-Zubieta, J.A., Galindo-Rodriguez, G., Robledo, I., Long-term effectiveness of danazol, corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus (2003) Lupus, 12, pp. 52-57Alba, P., Karim, M.Y., Hunt, B.J., Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome (2003) Lupus, 12, pp. 633-635Wang, S.-W., Cheng, T.-T., Systemic lupus erythematosus with refractory hemolytic anemia effectively treated with cyclosporin-A (2005) Lupus, 14, pp. 483-485Pignon, J.M., Poirson, E., Rochant, H., Danazol in autoimmune haemolytic anaemia (1993) Br J Haematol, 83, pp. 343-345Perotta, S., Locatelli, F., La Manna, A., Anti-CD20 monoclonal antibody (rituximabe) for life-threatning autoimmune hemolytic anaemia in a patient with systemic lupus erythematosus (2002) Br J Haematol, 116, pp. 465-467Majer, R.V., Hyde, R.D., High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia (1988) Clin Lab Haematol, 10, pp. 391-395Kondo, H., Date, Y., Sakai, Y., Effective simultaneous rhG-CSF and methylprednisolone pulse therapy in agranulocytosis associated with systemic lupus erythematosus (1994) Am J Hematol, 46, pp. 157-158Euler, H.H., Harten, P., Zeuner, R.A., Recombinant human granulocyte colony stimulating factor in patients with systemic lupus erythematosus associated neutropenia and refractory infections (1997) J Rheumatol, 24, pp. 215-237Cervera, H., Jara, L.J., Pizarro, S., Danazol for systemic lupus erythematosus with refractory autoimmune thrombocytopenia or Evans syndrome (1995) J Rheumatol, 22, pp. 1867-1871Roach, B.A., Hutchinson, G.J., Treatment of refractory, systemic lupus erythematosusassociated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide (1993) Arthritis Rheum, 36, pp. 682-684Arnal, C., Piette, J.C., Leone, J., Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases (2002) J Rheumatol, 29, pp. 75-83Goebel, K.M., Gassel, W.D., Goebel, F.D., Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus (1973) Scand J Haematol, 10, pp. 28-34Vasoo, S., Thumboo, J., Fong, K.Y., Refractory immune thrombocytopenia in systemic lupus erythematosus: Response to mycophenolate mofetil (2003) Lupus, 12, pp. 630-632Quartucio, L., Sacco, S., Franzolini, N., Efficacy of cyclosporin-A in the long-term management of thrombocytopenia associated with systemic lupus erythematosus (2006) Lupus, 15, pp. 76-79Shanafelt, T.D., Madueme, H.L., Wolf, R.C., Rituximab for immune cytopenia in adults: Idiopathic thrombocytopenic purpura,autoimmune hemolytic anemia,and Evans syndrome (2003) Mayo Clin Proc, 78, pp. 1340-1346Ten Cate, R., Smiers, F.J., Bredius, R.G., Anti-CD20 monoclonal antibody(rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus (2004) Rheumatology (Oxford), 43, p. 244Ter Borg, E.J., Kallenberg, C.G., Treatment of severe thrombocy-topenia in systemic lupus erythematosus with intravenous gammaglobulin (1992) Ann Rheum Dis, 51, pp. 1149-1151Chandramouli, N.B., Rodgers, G.M., Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia (2000) Am J Hematol, 65, pp. 85-86You, N.Y., Tefferi, A., Nagorney, D.M., Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus (2004) Ann Surg, 240, pp. 286-296Maksimowicz-McKinnon, K., Manzi, S., Cardiovascular manifestations of lupus (2007) Dubois lupus erythematosus, pp. 663-677. , Wallace DJ, Hahn BH, editors, Philadelphia: Lippincott Williams & Wilkins;Westerweel, P.E., Luyten, R.K., Koomans, H.A., Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus (2007) Arthritis Rheum, 56 (5), pp. 1384-1396Manzi, S., Meilahn, E.N., Rairie, J.E., Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study (1997) Am J Epidemiol, 145 (5), pp. 408-415Petri, M., Lakatta, C., Magder, L., Goldman, D., Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: A longitudinal data analysis (1994) Am J Med, 96, pp. 254-259Petri, M., Kiani, A.N., Post, W., Magder, L., Lupus Atherosclerosis Preventio Study (LAPS): A randomized double blind placebo controlled trial of atorvastatin versus placebo (2006) Arthritis Rheum, 54 (SUPPL.), p. 520. , SFerreira, G.A., Navarro, T.P., Telles, R.W., Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: An 8 weeks controlled trial (2007) Rheumatology (Oxford), 46 (10), pp. 1560-1565D'Cruz D, Khamashta MA, Hughes G: Pulmonary manifestations of systemic lupus erythematosus. In: Wallace DJ, Hahn BH. Dubois' Lupus Erythematosus. Philadelphia, 7th ed. Lippincott Williams & Wilkins2007. p. 678-99Man, B.L., Mok, C.C., Serositis related to systemic lupus erythematosus: Prevalence and outcome (2005) Lupus, 14, pp. 822-826Kao, A.H., Manzi, S., How to manage patients with cardiopulmonary disease? (2002) Best Pract Res Clin Rheumatol, 16, pp. 211-227McKnight, K.M., Adair, N.E., Agudelo, C.A., Successful use of tetracycline pleurodesis to treat massive pleural effusion secondary to systemic lupus erythematosus (1991) Arthritis Rheum, 34, pp. 1483-1484Schwab, E.P., Schumacher Jr, H.R., Freundlich, B., Callegari, P.E., Pulmonary alveolar hemorrhage in systemic lupus erythematosus (1993) Semin Arthritis Rheum, 23, pp. 8-15Weinrib, L., Sharma, O.P., Quismorio Jr, F.P., A long-term study of interstitial lung disease in systemic 1upus erythematosus (1990) Semin Arthritis Rheum, 20, pp. 48-56Okada, M., Suzuki, K., Matsumoto, M., Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases (2007) Mod Rheumatol, 17, pp. 131-136Heresi, G.A., Minai, O.A., Lupus-associated pulmonary hypertension: Long-term response to vasoactive therapy (2007) Respir Med, 101, pp. 2099-2107Denton, C.P., Humbert, M., Rubin, L., Black, C.M., Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: A subgroup analysis of the pivotal clinical trials and their open-label extensions (2006) Ann Rheum Dis, 65, pp. 1336-1340Galiè, N., Manes, A., Farahani, K.V., Pulmonary arterial hypertension associated to connective tissue diseases (2005) Lupus, 14, pp. 713-717Sanchez, O., Sitbon, O., Jaïs, X., Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension (2006) Chest, 130, pp. 182-189The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42: 599-608, 1999Boumpas, D.T., Yamada, H., Patronas, N.J., Pulse cyclophosphamide for severe neuropsychiatric lupus (1991) Q J Med, 81, pp. 975-984West SG: The nervous system. In: Wallace DJ, Hahn BH. Dubois' Lupus Erythematosus. Philadelphia. 7th ed. Lippincott Williams & Wilkins2007. p. 707-46Barile, L., Lavalle, C., Transverse myelitis in systemic lupus erythematosus - the effect of IV pulse methylprednisolone and cyclophosphamide (1992) J Rheumatol, 19, pp. 370-372Tokunaga, M., Saiko, K., Kawabata, D., Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system (2007) Ann Rheum Dis, 66, pp. 470-475Dooley MA: Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH. Dubois' Lupus Erythematosus. Philadelphia, 7th ed. Lippincott Williams & Wilkins2007. p. 1112-30Grande, J.P., Ballow, J.E., Renal biopsy in lupus nephritis (1998) Lupus, 7, pp. 611-617Weening, J.J., D'Agati, V.D., Schwartz, M.M., The classification of glomerulonephritis in systemic lupus erythematosus revisited (2004) J Am Soc Nephrol, 15 (2), pp. 241-250Weening, J.J., D'Agati, V.D., Schwartz, M.M., The classification of glomerulonephritis in systemic lupus erythematosus revisited (2004) Kidney Int, 65 (2), pp. 521-530The American College of Rheumatology response criteria for proliferative and membranous renal disease in SLE clinical trials (2006) Arthritis Rheum, 54, pp. 421-432. , Renal disease subcommitee of the ACRAd Hoc Committee on SLE response criteriaRuggenenti, P., Perna, A., Gherardi, G., Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy (1998) Lancet, 352, pp. 1252-1256Praga, M., Slowing the progression of renal failure (2002) Kidney Int, (SUPPL. 80), pp. 18-22Pollak, V.E., Treatment of lupus nephritis (1983) Nippon Jinzo Gakkai Shi, 25, pp. 776-785Kimberly, R.P., Lockshin, M.D., Sherman, R.L., High-dose intravenous methylprednisolone pulse therapy in systemic lupus erythematosus (1981) Am J Med, 70, pp. 817-824Austin 3rd, H.A., Klippel, J.H., Balow, J.E., Therapy of lupus nephritis: Controlled trial of prednisone and cytotoxic drugs (1986) N Engl J Med, 314, pp. 614-619Balow, J.E., Choosing treatment for proliferative lupus nephritis (2002) Arthritis Rheum, 46, pp. 1981-1983Flanc, R.S., Roberts, M.A., Strippoli, G.F., Treatment of diffuse proliferative lupus nephritis: A meta-analysis of randomized controlled trials (2004) Am J Kidney Dis, 43, pp. 197-208Bansal, V.Y., Beto, J.A., Treatment of lupus nephritis: A meta-analysis of clinical trials (1997) Am J Kidney Dis, 29, pp. 193-199Chan, T.M., Li, F.K., Tang, C.S., Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis (2000) Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med, 343, pp. 1156-1162Houssiau, F.A., Vasconcelos, C., D'Cruz, D., Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide (2002) Arthritis Rheum, 46, pp. 2121-2131Contreras, G., Pardo, V., Leclercq, B., Sequential therapies for proliferative lupus nephritis (2004) N Engl J Med, 350, pp. 971-980Ginzler, E.M., Aranow, C., Buyon, J., A multicenter study of MMF Vs IV cyclophosphamide as induction therapy for severe lupus nephritis: Preliminary results (2005) N Eng J Med, 353, pp. 2219-2228Sinclair, A., Appel, G., Dooley, M.A., Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: Rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS) (2007) Lupus, 16 (12), pp. 972-980Kolasinski, S.L., Chung, J.B., Albert, D.A., What do we know about lupus membranous nephropathy? An analytic review (2002) Arthritis Rheum, 47, pp. 450-455Chan, T.M., Li, F.K., Hao, W.K., Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression (1999) Lupus, 8, pp. 545-551Radhakrishnan, J., Kunis, C.L., D'Agati, V., Appel, G.B., Cyclosporine treatment of lupus membranous nephropathy (1994) Clin Nephrol, 42, pp. 147-154Mok, C.C., Ying, K.Y., Lau, C.S., Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: An open-label trial (2004) Am J Kidney Dis, 43, pp. 269-276Botha, E.F., Guedes, L.K., Christmann, R.B., Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria (2006) Rheumatol Int, 26 (12), pp. 1078-1083Sabahi, R., Anolik, J.H., B-cell-target for SLE (2006) Drugs, 66 (15), pp. 1933-1948Bhat, P., B lymphocytes and lupus nephritis: New insights into pathogenesis and targeted therapies (2008) Kidney Int, 73, pp. 261-268Stone, J.H., End-stage renal disease in lupus: Disease activity, dialysis, and the outcome of transplantation (1998) Lupus, 7, pp. 654-659Urowitz, M.B., Gladman, D.D., Farewell, V.T., Lupus and pregnancy studies (1993) Arthritis Rheum, 36, pp. 1392-1397Clowaw, M.E., Magder, L.S., Petri, M., The impact of increased lupus activity on obstetric outcomes (2005) Arthritis Rheum, 52, pp. 514-521Sánchez-Guerrero, J., Uribe, A.G., Jiménez-Santana, L., A trial of contraceptive methods in women with Systemic lupus erythematosus (2005) N Engl J Med, 353, pp. 2539-2549Petri, M., Kim, M.Y., Kalunian, K.C., OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus (2005) N Engl J Med, 353, pp. 2550-2558Buyon, J.P., Kalunian, K.C., Ramsey-Goldman, R., Assessing disease activity in SLE patients during pregnancy (1999) Lupus, 8, pp. 677-684Petri, M., (2003) Pregnancy in SLE, pp. 1427-1430. , ed. Rheumatology. 3th. ED;Wilson, W.A., Gharavi, A.E., Koike, T., International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop (1999) Arthritis Rheum, 42, pp. 1309-1311Buyon, J.P., Clancy, R.M., Neonatal lupus syndromes (2003) Curr Opin Rheumatol, 15, pp. 535-541Cervera, R., Font, J., Carmona, F., Balasch, J., Pregnancy outcome in systemic lupus erythematosus: Good news for the new millennium (2002) Autoimmun Rev, 1, pp. 354-359Anderson, P.O., Drugs and breast feeding (1979) Semin Peri